Synektik (SNTP) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
21 Aug, 2026Executive summary
Consolidated revenue for 9M FY2025 rose 52% year-over-year to PLN 733.4 million, driven by strong growth in medical equipment and IT solutions sales, as well as maintenance and measurement services.
EBITDA from continuing operations increased 55% to PLN 189.6 million for 9M FY2025.
Net profit from continuing operations rose 61% year-over-year to PLN 138.0 million, with total comprehensive income at PLN 386.4 million, including a non-cash gain from the demerger of PLN 261.3 million.
The Group completed a significant demerger, transferring the cardiotracer project and Center for Research on New Compounds to Syn2bio SA, resulting in a one-time gain and a reduction in equity.
Significant growth in equipment and IT solutions sales, international expansion, and record contract awards.
Financial highlights
Q3 FY2025 revenue reached PLN 292.3 million, up 89% year-over-year.
Q3 FY2025 EBITDA from continuing operations was PLN 71.5 million, up 72% year-over-year.
Q3 FY2025 net profit from continuing operations rose 80% to PLN 55.1 million.
Operating profit (EBIT) for the nine months was PLN 173.8 million, up from PLN 107.5 million year-over-year.
Positive operating cash flow of PLN 141.4 million over 9M FY2025; net cash position of PLN 35.7 million as of June 30, 2026.
Outlook and guidance
Entered final quarter of 2025 with a backlog and active offers totaling PLN 205 million, a 21% year-over-year increase.
Preparations underway for launch of operations in Ukraine and commercial launch of Edison system in Poland.
Management anticipates continued growth in sales of medical equipment, IT, and maintenance services, supported by higher public healthcare investment and an expanding product portfolio.
Expansion in surgical robotics, especially in Poland and new markets such as Ukraine, is expected to drive future results.
Recurring revenue from services and consumables is projected to increase due to a growing installed base and higher device utilization.
Latest events from Synektik
- Record revenue and profit growth, strong backlog, and Syn2bio spin-off drive positive outlook.SNTP
Q2 2026 - Revenue and EBITDA surged year-over-year, driven by recurring sales and segment expansion.SNTP
Q4 2024 - Double-digit revenue and profit growth, record dividend, and strategic expansion initiatives.SNTP
Q1 2026 - 9% revenue growth, 24% EBITDA increase, and strategic R&D spin-off highlight strong results.SNTP
Q4 2025 - Revenue and EBITDA soared on strong medical equipment and recurring sales, with robust outlook.SNTP
Q2 2024 - Revenue up 55% and net profit up 74% year-over-year, with strong growth in all key segments.SNTP
Q3 2024 - Recurring and radio-pharmaceutical revenues rose, margins improved, and strategic expansion continued.SNTP
Q1 2025 - Recurring revenue growth and margin improvement offset lower sales, supporting future expansion.SNTP
Q2 2025 - Q3 revenue up 24% YoY, EBITDA up 31%, with R&D spin-off and strong recurring revenue growth.SNTP
Q3 2025